Novavax NVAX Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's business segments — cost of sales?
- Novavax (NVAX) reported business segments — cost of sales of $30.7M in Q1 2026.
- How has Novavax's business segments — cost of sales changed year-over-year?
- Novavax's business segments — cost of sales increased by 117.5% year-over-year, from $14.12M to $30.7M.
- What is the long-term trend for Novavax's business segments — cost of sales?
- Over 3 years (2022 to 2025), Novavax's business segments — cost of sales has grown at a -56.7% compound annual growth rate (CAGR), from $902.64M to $73.04M.
- What does business segments — cost of sales mean?
- Includes the direct costs attributable to the production and delivery of goods or services sold by the reportable segment. Monitoring this metric is essential for evaluating the segment's gross margin efficiency and the direct impact of manufacturing or supply chain costs on profitability.